Literature DB >> 1374585

Comparison of an immunoperoxidase "sandwich" staining method and western blot detection of P-glycoprotein in human cell lines and sarcomas.

K Tóth1, M M Vaughan, H K Slocum, W J Fredericks, Y F Chen, M A Arredondo, A Harstrick, C Karakousis, R M Baker, Y M Rustum.   

Abstract

The applicability of a multilayer immunoperoxidase "sandwich" method (IpS) developed by Chan14 for the amplified detection of P-glycoprotein (Pgp) was investigated. The authors examined 15 formalin-fixed cell lines, as well as formalin-fixed, paraffin-embedded sections from single biopsies of 46 sarcomas. The cell lines included sensitive and multidrug resistant sublines (KB, A2780, MCF-7, HeLa) with various relative degrees of resistance to doxorubicin (Dox). The sarcoma biopsy specimens were selected on the basis of the results obtained in Western blot (WB) detection of Pgp (22 positive and 24 negative by WB) using C219 and C494 monoclonal antibodies to Pgp. The IpS method employed C219. The least resistant cell line in which Pgp could be detected by IpS was fivefold resistant to doxorubicin, whereas Pgp was detected by WB in cells greater than twofold resistant. Cell lines having greater than fivefold resistance to Dox were positive by both IpS and WB analyses. The less resistant cell lines contained more nonreactive cells whereas the highly resistant cell lines showed more homogeneous strong membrane reactions. Among the six cell lines determined to be Pgp negative by WB analysis, no false positive immunostaining by IpS existed. One of 22 WB positive and 7 of 24 WB-negative sarcoma biopsy specimens were positive by IpS methods. Reaction varied and was always focal (a minimum of 3-5 cells, ranging up to 3-4 high power fields) indicating pronounced heterogeneous distribution of Pgp. Thus, WB can detect low average (overall) levels of Pgp in tumor samples but such low concentrations of PgP at the single cell are not detectable by IpS methods. However, IpS can discern among many Pgp-negative cells small subpopulations of immunoreactive cells, which are not detected by WB analysis due to Pgp dilution by the membrane protein of numerous Pgp negative cells. IpS and WB used together as complementary methods can provide more complete information about Pgp distribution and content, particularly in the case of heterogeneous human tumors. The IpS method is more suitable for less drastically treated (not embedded) cell line specimens than for paraffin-embedded (routine) sections. Some modification of the present IpS protocol seems necessary to increase its sensitivity and reduce the disparity with WB results.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1374585      PMCID: PMC1886523     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  24 in total

1.  Expression of a multidrug-resistance gene in human tumors and tissues.

Authors:  A T Fojo; K Ueda; D J Slamon; D G Poplack; M M Gottesman; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

2.  Comparison of western blot analysis and immunocytochemical detection of P-glycoprotein in multidrug resistant cells.

Authors:  M L Friedlander; D R Bell; J Leary; R A Davey
Journal:  J Clin Pathol       Date:  1989-07       Impact factor: 3.411

3.  Isolation of amplified and overexpressed DNA sequences from adriamycin-resistant human breast cancer cells.

Authors:  C R Fairchild; S P Ivy; C S Kao-Shan; J Whang-Peng; N Rosen; M A Israel; P W Melera; K H Cowan; M E Goldsmith
Journal:  Cancer Res       Date:  1987-10-01       Impact factor: 12.701

4.  Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16.

Authors:  I Sugawara; I Kataoka; Y Morishita; H Hamada; T Tsuruo; S Itoyama; S Mori
Journal:  Cancer Res       Date:  1988-04-01       Impact factor: 12.701

5.  Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies.

Authors:  E Georges; G Bradley; J Gariepy; V Ling
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

6.  Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis.

Authors:  R S Weinstein; S M Jakate; J M Dominguez; M D Lebovitz; G K Koukoulis; J R Kuszak; L F Klusens; T M Grogan; T J Saclarides; I B Roninson
Journal:  Cancer Res       Date:  1991-05-15       Impact factor: 12.701

7.  P-glycoprotein in human sarcoma: evidence for multidrug resistance.

Authors:  J H Gerlach; D R Bell; C Karakousis; H K Slocum; N Kartner; Y M Rustum; V Ling; R M Baker
Journal:  J Clin Oncol       Date:  1987-09       Impact factor: 44.544

Review 8.  Expression and functions of P-glycoprotein (mdr1 gene product) in normal and malignant tissues.

Authors:  I Sugawara
Journal:  Acta Pathol Jpn       Date:  1990-08

Review 9.  P-glycoproteins in pathology: the multidrug resistance gene family in humans.

Authors:  R S Weinstein; J R Kuszak; L F Kluskens; J S Coon
Journal:  Hum Pathol       Date:  1990-01       Impact factor: 3.466

10.  Immunohistochemical detection of multidrug resistance associated P-glycoprotein in tumour and stromal cells of human cancers.

Authors:  D Schlaifer; G Laurent; S Chittal; T Tsuruo; S Soues; C Muller; J Y Charcosset; C Alard; P Brousset; C Mazerrolles
Journal:  Br J Cancer       Date:  1990-08       Impact factor: 7.640

View more
  2 in total

Review 1.  P-glycoprotein structure and evolutionary homologies.

Authors:  J M Croop
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

2.  New immunohistochemical "sandwich" staining method for mdr1 P-glycoprotein detection with JSB-1 monoclonal antibody in formalin-fixed, paraffin-embedded human tissues.

Authors:  K Tóth; M M Vaughan; H K Slocum; M A Arredondo; H Takita; R M Baker; Y M Rustum
Journal:  Am J Pathol       Date:  1994-02       Impact factor: 4.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.